On January 21, 2022 the FDA approved AbbVie’s Skyrizi® (risankizumab-rzaa) for the treatment of adult patients with psoriatic arthritis. Psoriatic arthritis (PsA), a systemic inflammatory disease, is a complication of psoriasis that is characterized by joint pain, stiffness and swelling that impacts an estimated 30% of individuals with psoriasis. While no cure for PsA exists, there are treatments available aimed at improving patients’ quality of life by controlling symptoms and preventing further joint damage. The safety and efficacy of Skyrizi® in the treatment of PsA was evaluated in two clinical trials, KEEPsAKE-1 and KEEPsAKE-2. Both trials enrolled adult patients with active PsA and included those who had inadequate responses or intolerance to biologic therapies and/or non-biologic disease-modifying antirheumatic drugs (DMARDs). Skyrizi® was dosed as a single 150 mg injection under the skin at weeks 0, 4, and 16, with results measured at 24 weeks. The primary endpoint of the studies was measurement of ACR20 response (an improvement of 20% in the number of tender and swollen joints). Over 50% of patients who received Skyrizi® achieved the primary endpoint of ACR20 response at week 24 in both trials, versus 33.5% and 26.5% of patients who received placebo in KEEPsAKE-1 and KEEPsAKE-2 respectively. This approval of Skyrizi® will provide dermatologists and rheumatologists with an additional treatment option to help improve skin and joint symptoms in patients with PsA.